− CHMP konkluderede, at benefit/ risk- forholdet for systemiske formuleringer af lægemidler indeholdende piroxicam til de vedtagne begrænsede indikationer er gunstigt.
− The CHMP concluded that the benefit/ risk balance of systemic formulations of piroxicam containing medicinal products in the agreed restricted indications is favourable.